Evidence map›Paper›PMID 40802119›Full record

ArticleJournal of neuro-oncology2025

Real-world experience outcome in patients with central nervous system metastases: information on 2,226 patients during a 15-year period.

Oscar Arrieta, Alexandra Díaz-Alba, Sergio Moreno-Jiménez, Alejandro Rodríguez-Camacho, Enrique Caballe-Pérez, Marco Antonio Rodríguez-Florido, Alberto González-Aguilar, Ytel Garcilazo-Reyes, Mónica Alicia Sierra-Del-Río, Fernando Alcides Lozano-Sánchez and 2 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Oscar ArrietaThoracic Oncology Unit, Instituto Nacional de Cancerología, Mexico City, Mexico.ORCID http://orcid.org/0000-0002-1164-3779
Alexandra Díaz-AlbaClínica de tumores cerebrales, Instituto Jaliscience de Cancerología, Guadalajara, Mexico City, Jalisco, Mexico.ORCID http://orcid.org/0000-0003-3282-7531
Sergio Moreno-JiménezInstituto Nacional de Neurología y Neurocirugía & Centro Neurológico, Centro Médico ABC, Mexico City, Mexico.ORCID http://orcid.org/0000-0001-9932-0917
Alejandro Rodríguez-CamachoUnidad Funcional de Neuro-Oncología, Instituto Nacional de Cancerología, Mexico City, Mexico.ORCID http://orcid.org/0000-0002-0486-4039
Enrique Caballe-PérezThoracic Oncology Unit, Instituto Nacional de Cancerología, Mexico City, Mexico.ORCID http://orcid.org/0000-0001-7703-6675
Marco Antonio Rodríguez-FloridoHospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguto Social, Mexico City, Mexico.ORCID http://orcid.org/0000-0003-4659-6324
Alberto González-AguilarCentro Oncológico Internacional (COI), Mexico City, Mexico.ORCID http://orcid.org/0000-0001-8916-6258
Ytel Garcilazo-ReyesNeuro-Oncology Division, Centro Oncológico Internacional (COI), Mexico City, Mexico.ORCID http://orcid.org/0000-0001-6154-1511
Mónica Alicia Sierra-Del-RíoHospital Regional de alta especialidad del Bajío, León, Guanajuato, Mexico.ORCID http://orcid.org/0009-0000-5900-0927
Fernando Alcides Lozano-SánchezUnidad de Neurología y Neuro-Oncología, Monterrey, Mexico City, Nuevo León, Mexico.ORCID http://orcid.org/0000-0003-0807-4090
Bernardo Cacho-DíazUnidad Funcional de Neuro-Oncología, Instituto Nacional de Cancerología, Mexico City, Mexico. bernardocacho@doctor.com.ORCID http://orcid.org/0000-0001-9289-5312
CACHO (Central nervous system Activity in Cancer and Hemato-Oncologic diseases) network

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeMost data regarding Central nervous system (CNS) metastases are derived from non-Hispanic populations enrolled in clinical trials. This study aims to characterize the primary tumors, initial treatments, and outcomes in a Hispanic/Latino real-world population with CNS metastases.

methodsA retrospective analysis of a multicenter cohort of patients with CNS metastases treated from 2010 to 2024.

resultsFrom 2,261 patients with CNS metastases, 84% had brain metastases and 16% had neoplastic meningitis. The most common primary tumors were breast (40%), lung (27%), genitourinary (11%), gynecologic (6%), and melanoma (4%). Whole-brain radiotherapy and systemic therapy were initially prescribed in 84% and 55% of cases, respectively. The median overall survival was 9.8 months (95% CI, 8.9 - 10.7). Variables associated with outcomes included location of the primary tumor, molecular subtype, type of CNS metastases (brain metastases vs. neoplastic meningitis), and access to targeted therapies.

conclusionIn a real-world cohort of Hispanic/Latino patients with CNS metastases, survival has remained poor over the past 15 years. This highlights the need for interventions and research to improve outcomes.

Indexed as

Central Nervous System NeoplasmsAdultAgedAged, 80 and overBrain NeoplasmsFemaleFollow-Up StudiesHispanic or LatinoHumansMaleMexicoMiddle AgedPrognosisRetrospective StudiesSurvival RateTreatment OutcomeBrain metastasesCNS metastasesHispanicLatinoNeoplastic meningitis

Identifiers

PMID40802119

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.